We have avidly read the recent study, “Serum bile acids in cystic fibrosis patients
– glycodeoxycholic acid as a potential marker of liver disease” by Sawomira Drzymaa-czy
et al. [
[1]
] and we commend the authors for their diligent work. Numerous studies demonstrate
that cystic fibrosis and its related liver disease can induce changes in bile acid
metabolism. We agree with the study's summary that a CF-related specific bile acid
profile is associated with liver disease and glycodeoxycholic acid distinguishes patients
with non-cirrhotic liver involvement from those without detectable liver disease.
Therefore, glycodeoxycholic acid has potential to be a valid biomarker of non-cirrhotic
liver disease development in CF. However, we believe it is necessary to include other
significant aspects that would improve the quality of this article and add to our
understanding of chronic hepatic diseases.- Drzymała-Czyż S.
- Dziedzic K.
- Szwengiel A.
- Krzyżanowska-Jankowska P.
- Nowak J.K.
- Nowicka A.
- Aringazina R.
- Drzymała S.
- Kashirskaya N.
- Walkowiak J
Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential
marker of liver disease.
Dig Liver Dis. 2022; 54 (Epub 2021 Jul 22. PMID:34305015): 111https://doi.org/10.1016/j.dld.2021.06.034
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease.Dig Liver Dis. 2022; 54 (Epub 2021 Jul 22. PMID:34305015): 111https://doi.org/10.1016/j.dld.2021.06.034
- Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study.J Cyst Fibros. 2022; 21 (Epub 2021 Apr 2. PMID:33814323): 220-226https://doi.org/10.1016/j.jcf.2021.03.014
- The Detection of Bile Acids in the Lungs of Paediatric Cystic Fibrosis Patients Is Associated with Altered Inflammatory Patterns.Diagnostics (Basel). 2020 May 6; 10 (PMID:32384684 PMCID: PMC7277992): 282https://doi.org/10.3390/diagnostics10050282
- IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.J Cyst Fibros. 2019; 18 (Epub 2018 Sep 29. PMID:30279125): 286-293https://doi.org/10.1016/j.jcf.2018.09.001
- Bile Acid Signal Molecules Associate Temporally with Respiratory Inflammation and Microbiome Signatures in Clinically Stable Cystic Fibrosis Patients.Microorganisms. 2020; 8 (PMID:33172004 PMCID: PMC7694639): 1741https://doi.org/10.3390/microorganisms8111741
Article info
Publication history
Published online: August 24, 2022
Accepted:
August 4,
2022
Received:
July 15,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Serum bile acids in cystic fibrosis patients – glycodeoxycholic acid as a potential marker of liver diseaseDigestive and Liver DiseaseVol. 54Issue 1
- Author's reply: “Serum bile acids in cystic fibrosis patients—Glycodeoxycholic acid as a potential marker of liver disease”Digestive and Liver DiseaseVol. 54Issue 11
- PreviewWe have read with interest the comments [1] on our recent article, which showed that glycodeoxycholic acid discriminates between cystic fibrosis (CF) patients with non-cirrhotic liver involvement and no detectable disease (AUC: 0.924, 95%CI 0.822–1.000, p < 0.001) [2]. Given this result, we do not share the concern that sample size is an issue. Please note that to include 25 patients with liver cirrhosis, as defined in our study, we needed to screen almost 1000 patients in total (nearly half of the national population).
- Full-Text
- Preview
